ID
45546
Description
Principal Investigator: Yick Fu Wong, Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA MeSH: Uterine Cervical Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000723 Precision mapping of genetic alterations in cancer can enable better selection of therapies and improved outcomes when combined with new sequencing diagnostics. We describe whole-exome sequences from cervical adenocarcinomas and paired normal samples in Hong Kong Chinese women. These data uncover a heterogeneous genomic landscape but identify commonly aberrant loci including FAT1, ARID1A, ERBB2 and PIK3CA that may provide a focus for the development of individualized targeted therapies for Chinese women with cervical adenocarcinoma.
Link
Keywords
Versions (1)
- 1/6/23 1/6/23 - Chiara Middel
Copyright Holder
Yick Fu Wong, Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
Uploaded on
January 6, 2023
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
dbGaP phs000723 Sequencing of Cervical Cancer
Sample ID, body site, analyte type, tumor status of samples, histological type, primary metastatic tumor, primary tumor location, tumor stage, tumor grade, tumor treatment, genotyping center, and sequencing center of participants with or without cervical cancer and involved in the "Sequencing of Cervical Cancer" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, source subject ID, and affection status of participants with or without cervical cancer and involved in the "Sequencing of Cervical Cancer" project.
- Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with or without cervical cancer and involved in the "Sequencing of Cervical Cancer" project.
- Subject ID, age, clinical stage, gender, race, HPV genotyping, and integrated HPVs at exons of participants with or without cervical cancer and involved in the "Sequencing of Cervical Cancer" project.
- Sample ID, body site, analyte type, tumor status of samples, histological type, primary metastatic tumor, primary tumor location, tumor stage, tumor grade, tumor treatment, genotyping center, and sequencing center of participants with or without cervical cancer and involved in the "Sequencing of Cervical Cancer" project.
Similar models
Sample ID, body site, analyte type, tumor status of samples, histological type, primary metastatic tumor, primary tumor location, tumor stage, tumor grade, tumor treatment, genotyping center, and sequencing center of participants with or without cervical cancer and involved in the "Sequencing of Cervical Cancer" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, source subject ID, and affection status of participants with or without cervical cancer and involved in the "Sequencing of Cervical Cancer" project.
- Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with or without cervical cancer and involved in the "Sequencing of Cervical Cancer" project.
- Subject ID, age, clinical stage, gender, race, HPV genotyping, and integrated HPVs at exons of participants with or without cervical cancer and involved in the "Sequencing of Cervical Cancer" project.
- Sample ID, body site, analyte type, tumor status of samples, histological type, primary metastatic tumor, primary tumor location, tumor stage, tumor grade, tumor treatment, genotyping center, and sequencing center of participants with or without cervical cancer and involved in the "Sequencing of Cervical Cancer" project.
C1299222 (UMLS CUI [1,2])
C1518422 (UMLS CUI [1,2])
C0007634 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C2347026 (UMLS CUI [2,1])
C0007634 (UMLS CUI [2,2])
C0449560 (UMLS CUI [2,3])
C1292533 (UMLS CUI [3,1])
C0332307 (UMLS CUI [3,2])
C1292533 (UMLS CUI [4,1])
C0449560 (UMLS CUI [4,2])
C0027627 (UMLS CUI [2,1])
C0007601 (UMLS CUI [3,1])
C0370003 (UMLS CUI [1,2])
C0370003 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])
C0370003 (UMLS CUI [1,3])
C0565990 (UMLS CUI [1,2])
C0565990 (UMLS CUI [1,2])
C1561491 (UMLS CUI [1,3])